Abstract
This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms (SNPs) in a naturalistic cohort of first episode psychosis (FEP) patients. Two hundred and two SNPs in 31 candidate genes (involved in dopamine, serotonin and glutamate pathways) were analyzed in the present study. One hundred and thirteen FEP patients (43 presenting EPS and 70 non-presenting EPS) treated with high-potency AP (amisulpride, paliperidone, risperidone and ziprasidone) were included in the analysis. The statistical analysis was adjusted by age, gender, AP dosage, AP combinations and concomitant treatments as covariates. Four SNPs in different genes (DRD2, SLC18A2, HTR2A and GRIK3) contributed significantly to the risk of EPS after correction for multiple testing (P<1 × 10−4). These findings support the involvement of dopamine, serotonin and glutamate pathways in AP-induced EPS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–962.
Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012; 38: 167–177.
Divac N, Prostran M, Jakovcevski I, Cerovac N . Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int 2014; 2014: 656370.
Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 809–815.
Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gassó P et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 2007; 90: 115–122.
Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gassó P et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008; 161: 131–141.
Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007; 17: 519–528.
Gassó P, Mas S, Bernardo M, Alvarez S, Parellada E, Lafuente A . A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 2009; 9: 404–410.
Lawford BR, Barnes M, Swagell CD, Connor JP, Burton SC, Heslop K et al. DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. J Psychopharmacol 2013; 27: 343–348.
Zivković M, Mihaljević-Peles A, Bozina N, Saqud M, Nikolac-Perkovic M, Vuksan-Cusa B et al. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol 2013; 33: 593–599.
Güzey C, Scordo MG, Spina E, Landsem VM, Spigset O . Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 2007; 63: 233–241.
Gunes A, Scordo MG, Jaanson P, Dahl ML . Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacol (Berl) 2007; 190: 479–484.
Gunes A, Dahl ML, Spina E, Scordo MG . Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 2008; 64: 477–482.
Al-Janabi I, Arranz MJ, Blakemore AI, Saiz PA, Susce MT, Glasser PE et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 2009; 19: 305–311.
Wilffert B, Al Hadithy AF, Sing VJ, Matroos G, Hoek HW, van Os J et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African−Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009; 23: 652–659.
Creed-Carson M, Oraha A, Nobrega JN . Effects of 5-HT(2 A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res 2011; 219: 273–279.
Giegling I, Drago A, Dolžan V, Plesnicar BK, Schäfer M, Hartmann AM et al. Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenet Genomics 2011; 21: 206–216.
Drago A, Giegling I, Schäfer M, Hartmann AM, Möller HJ, De Ronchi D et al. No association of a set of candidate genes on haloperidol side effects. PLoS One 2012; 7: e44853.
Drago A, Giegling I, Schäfer M, Hartmann AM, Möller HJ, De Ronchi D et al. AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. Eur Neuropsychopharmacol 2013; 23: 887–894.
Tybura P, Trześniowska-Drukała B, Bienkowski P, Beszlej A, Frydecka D, Mierzejewski P et al. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Psychiatry Res 2014; 219: 261–267.
Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, Fernandez-Piqueras J et al. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics 2013; 23: 627–630.
Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller DD et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279–282.
Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B . Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacol (Berl) 2009; 206: 491–499.
Drago A, Crisafulli C, Serretti A . The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 975–986.
Haddad PM, Das A, Keyhani S, Chaudhry IB . Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol 2012; 26: 15–26.
Bernardo M, Bioque M, Parellada M, Saiz Ruiz J, Cuesta MJ, Llerena A et al. Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Rev Psiquiatr Salud Ment 2013; 6: 4–16.
American Psychiatric Association (Washington) DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC, USA, 1994.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100.
Simpson GM, Angus JW . A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–19.
Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ . International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686–693.
González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644–645.
Jakulin A, Bratko I . Analyzing attribute interactions. Lect Notes Artif Intell 2003; 2838: 229–240.
Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O . Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26: 192–197.
Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF et al. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin 2006; 27: 966–970.
Kaiser R, Tremblay PB, Klufmöller F, Roots I, Brockmöller J . Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7: 695–705.
Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639–651.
Bakker PR, van Harten PN, van Os J . Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544–556.
Chen JJ, Ondo WG, Dashtipour K, Swope DM . Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 2012; 34: 1487–1504.
Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman J, North KE et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 336–340.
Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res 2013; 47: 1760–1765.
Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR et al. Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African−Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 890–897.
Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN . Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One 2012; 7: e36561.
Knol W, van Marum RJ, Jansen PA, Strengman E, Al-Hadithy AF, Wilffert B et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol 2013; 33: 405–410.
Laje G, Cannon DM, Allen AS, Klaver JM, Peck SA, Liu X et al. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol 2010; 13: 715–724.
Crowley JJ, Kim Y, Szatkiewicz JP, Pratt AL, Quackenbush CR, Adkins DE et al. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 2012; 23: 322–335.
Ivanova SA, Loonen AJ, Pechlivanoglou P, Freidin MB, Al-Hadithy AF, Rudikov EV et al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl Psychiatry 2012; 2: e67.
Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacol 2010; 35: 1155–1164.
Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B . Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 2012; 12: 513–520.
Mas S, Llerena A, Saíz J, Bernardo M, Lafuente A . Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 2012; 13: 1773–1782.
Mas S, Gassò P, Alvarez S, Parellada E, Bernardo M, Lafuente A . Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 2012; 12: 255–259.
Acknowledgements
This study was supported by the Ministerio de Economía y Competitividad (Ref. ISCIII 2009-2011: PI 080208)- Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional-Unión Europea-Una manera de hacer Europa; the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); and by the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2014SGR441). FI-DGR-2013 Contract of the Agència de Gestió d’Ajuts Universitaris i de Recerca, AGAUR (2015 FI_B2 00100) to GM. This work was developed (in part) at the Centro Esther Koplowitz (Barcelona). SNP genotyping services were provided by the Spanish ‘Centro Nacional de Genotipado’ (CEGEN-ISCIII)’ (www.cegen.org).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
AA has received a trainee research staff grant awarded by the University of Barcelona (APIF-UB grants). AB has received grants from the Spanish Ministry of Science and Innovation (FIS). AL has received grants from the Spanish Ministry of Science and Innovation (FIS). AM has received financial support to attend meetings, travel support and served as a speaker from Otsuka and Janssen-Cilag. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Ferrari, Forest Research Institute, Gideon Richter, GlaxoSmithKline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Snafu-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Seventh European Framework Programme (ENBREC) and the Stanley Medical Research Institute. FC has received financial support to attend meetings, travel support and served as advisor or speaker for the following entities: Lilly, Janssen-Cilag, Lundbeck, Otsuka, the Spanish Ministry of Science and Innovation (CIBERSAM) and the Ministry of Science (Carlos III Institute). IB has received grants from CIBERSAM, Fundación Alicia Koplowitz and Institute de Salad Carlos III, and has received honoraria as a speaker for Janssen, as well as support from Otsuka for attending some conferences. MB has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Almirall, AMGEN, Eli Lilly, Ferrari, Forum Pharmaceuticals, Gideon, Hersill, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Roche and Servier, and has obtained research funding from the Spanish Ministry of Health, the Spanish Ministry of Science and Education, the Spanish Ministry of Economy and Competitiveness, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), by the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and the 7th Framework Program of the European Union. MB has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of Adamed, Ferrer, Janssen-Cilag, Lundbeck, Otsuka and Pfizer. The remaining authors declare no conflict of interest.
Additional information
PEPs GROUP Gisela Mezquida2,3,4, Ana Meseguer2,3,4, Enrique García Bernardo12, Mara Parellada3,13, Anna Alonso-Solís3,8, Eva Grasa3,8, Miryam Hernandez3,6, Monica Martinez Cengotitabengoa3,6, Fe Barcones3,5, Julio Arbej3,5, Julio Sanjuan3,14, Eduardo J Aguilar3,14, Antonio Balbuena3,15,16, Anna Mané3,15,16, Carla Torrent2,17, Eduard Vieta2,17, Immaculada Baeza2,18, Elena de la Serna2,18, Fernando Contreras3,19,20, Auria Albacete3,19,20, Maria Paz García-Portilla3,21, Julio Bobes3,21, Arantzazu Zabala Rabadán3,22, Rafael Segarra Echevarría3,22,23, Isabel Morales-Muñoz3,24, Roberto Rodriguez-Jimenez3,24, Anna Butjosa3,25, Judith Usall Rodie3,25, Salvador Sarró26, Ramón Landín-Romero26, Angela Ibañez Cuadrado3,10, Manuel J Cuesta27,28, Vicent Balanzá-Martínez.3,29 13Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Madrid, Spain; 14Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain; 15Clinic Hospital Valencia, INCLIVA, Valencia University, Valencia Spain; 16IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; 17Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain; 18Bipolar Disorders Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain; 19Child and adolescent Psychiatry and Psychology Department, Hospital Clínic de Barcelona, SGR-489, Barcelona, Spain; 20Department of Psychiatry, Bellvitge University Hospital-IDIBELL, Barcelona, Spain; 21Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain; 22Department of Psychiatry, University of Oviedo, Oviedo, Spain; 23Department of Neurosciences, BioCruces Health Research Institute, University of the Basque Country (UPV/EHU), Barakaldo, Spain; 24Department of Psychiatry, Cruces University Hospital, Barakaldo, Spain; 25Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; 26Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain; 27FIDMAG Hermanas Hospitalarias Research Foundation, Barcelona, Spain; 28Psychiatric Department, Complejo Hospitalario de Navarra, Pamplona, Spain; 29Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain and 30Mental Health Centre of Catarroja, University of Valencia, Valencia, Spain.
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mas, S., Gassó, P., Lafuente, A. et al. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J 16, 439–445 (2016). https://doi.org/10.1038/tpj.2016.44
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2016.44
This article is cited by
-
Damaging coding variants within kainate receptor channel genes are enriched in individuals with schizophrenia, autism and intellectual disabilities
Scientific Reports (2019)
-
Recent Progress in Pharmacogenomics of Antipsychotic Drug Response
Current Psychiatry Reports (2018)
-
Pharmacogenomics of Antipsychotic Drugs
Current Treatment Options in Psychiatry (2017)